Conversations with Oncology Investigators Bridging the Gap between Research and Patient Care

Submitted by nenadkesic@gmail.com on Thu, 09/21/2017 - 03:32

Listen to streaming audioright from your computer
Download programto your desktop
Sign up for podcastto have this and future issues delivered to your iTunes library

Audio Highlights

Interview with Professor Claire N Harrison, MD

Track 1:	Case discussion: A 67-year-old woman with JAK mutation-positive postpolycythemia vera myelofibrosis (post-PV MF) experiences an excellent clinical response to ruxolitinib after disease progression on hydroxyurea
Track 2:	Lack of correlation between JAK2 mutation status and response to ruxolitinib
Track 3:	Symptom improvement with ruxolitinib; dosing for patients with MF
Track 4:	Incidence and management of JAK2 inhibitor-associated herpes zoster
Track 5:	Duration of response to ruxolitinib
Track 6:	Treatment approaches for patients with MF and disease progression on ruxolitinib
Track 7:	Activity and ongoing investigations of novel JAK inhibitors in myeloproliferative neoplasms (MPNs)
Track 8:	Tolerability of ropeginterferon alfa-2b therapy for patients with PV
Track 9:	Case discussion: A 69-year-old man with primary MF experiences anemia while receiving ruxolitinib
Track 10:	Case discussion: A 43-year-old woman who initially presents with myocardial infarction is diagnosed with PV and receives ruxolitinib
Track 11:	Clinical experience with ruxolitinib in younger patients with PV
Track 12:	Long-term prognosis for younger patients with PV
Track 13:	JAK-STAT signaling in the therapeutic landscape of MPNs
Track 14:	Comprehensively understanding fatigue in patients with MPNs
Track 15:	Correlating cytokine levels with severity of fatigue
Track 16:	Pregnancy outcomes in patients with MPNs
Track 17:	Updated World Health Organization diagnostic criteria for MPNs

Interview with Srdan Verstovsek, MD, PhD

Track 1:	Effect of anemia on overall survival in patients with MF treated with ruxolitinib on the COMFORT studies
Track 2:	Case discussion: A 68-year-old woman with newly diagnosed, intermediate-1-risk MF and an EZH2 mutation
Track 3:	Case discussion: A 76-year-old man with MF and long-standing benefit from ruxolitinib
Track 4:	Case discussion: A 59-year-old man with MF and anemia requiring occasional transfusions
Track 5:	Case discussion: A 62-year-old man with a history of essential thrombocythemia (ET) presents with complete blood counts consistent with a diagnosis of PV
Track 6:	Case discussion: A 76-year-old man with PV previously controlled with hydroxyurea presents with pruritus
Track 7:	Case discussion: A 27-year-old woman presents with a platelet count of 1.7 million platelets per microliter and is diagnosed with ET
Track 8:	Clinical overview of MPNs
Track 9:	Alterations in the JAK-STAT signaling pathway in MPNs
Track 10:	Genetic mutation spectrum observed in MPNs
Track 11:	Polyclonality and MPNs: Age-related clonal hematopoiesis versus clonal evolution
Track 12:	Pathophysiology of splenomegaly associated with MF
Track 13:	Use of molecular testing for diagnosis of MPNs
Track 14:	Criteria for the diagnosis of PV
Track 15:	Diagnostic and risk stratification criteria for ET
Track 16:	First- and later-line treatment options for patients with PV
Track 17:	Natural disease course of MF and progression to acute myeloid leukemia
Track 18:	Novel treatment approaches under investigation for MF
Track 19:	Mechanism of action and activity of the telomerase inhibitor imetelstat in patients with MF and ET

FACULTY:

Professor Claire N Harrison, MD
Director of Hematology
Guy’s and St Thomas’ NHS
Foundation Trust
London, United Kingdom

Srdan Verstovsek, MD, PhD
Professor and Chief
Section for MPNs
Director, Clinical Research Center for
Myeloproliferative Neoplasia
Department of Leukemia
The University of Texas
MD Anderson Cancer Center
Houston, Texas

EDITOR:

Neil Love, MD
Research To Practice
Miami, Florida